CPClaudio Pedrinazzi

Claudio Pedrinazzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudio Pedrinazzi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 October 2010
      • Vol. 11, 102S-106S

    [Atrial fibrillation and flutter in athletes].

    by Giuseppe Inama, Claudio Pedrinazzi, Ornella Durin, Lorenza Inama, Francesco Furlanello

    Atrial fibrillation (AF) is one of the most frequent findings in the general population, with an incidence of about 0.1% per year and a mean prevalence of 0.95%. However, prevalence values are known to vary with age, being very low (0.1-0.2%) in subjects less than 55 years old, the age group comprising the greatest number of individuals who practice sport at various levels. Long-term, regular, intense physical training determines an increase in vagal tone, leading to bradycardia, and during physical activity, particularly competitive sport, a marked release of catecholamines occurs as a result of both the intense physical effort and the emotional stress involved in competition. Both these adaptive phenomena on the part of the autonomous nervous system may promote the development of AF. Heart diseases with a certain degree of severity are not generally compatible with sport, unless the activity undertaken involves a low expenditure of energy and is noncompetitive. In any case, in the presence of AF, the arrhythmia must be well controlled and well tolerated during performance of the activity.


    • 1 April 2010
      • Vol. 11  (4) , 329-40

    [Management of patients with palpitations. Consensus document of the AIAC (Italian Association of Arrhythmiology and Cardiostimulation].

    by Franco Giada, Giuseppe Inama, Manuel Bertaglia, Claudio Pedrinazzi, Michele Gulizia, Renato Ricci, Antonio Raviele, Associazione Italiana Di Aritmologia E Cardiostimolazione

  • Open Access

    Ventricular arrhythmias in competitive athletes: risk stratification with T-wave alternans

    by Giuseppe Inama, Claudio Pedrinazzi, Ornella Durin, Massimiliano Nanetti, Giorgio Donato, Rita Pizzi

    Introduction: Aim of our study is to evaluate the role of TWA to stratify the risk of sudden cardiac death in athletes (Ath) with complex ventricular arrhythmias (VA), and to document a possible correlation between TWA and electrophysiological testing (EES) results. Methods: We studied 43 Ath with VA (31 M, mean age 34 ± 12 years). In all cases a cardiological evaluation was performed, including TWA and EES. The patients were evaluated during a followup of 25 ± 22 months. The end-point was the occurrence of sudden death or malignant ventricular tachyarrhythmias (VT). Results: TWA was negative in 28 Ath (65%), positive in 8 (19%) and indeterminate in 7 (16%). All subjects with negative TWA did not show induction of VT at EES, with significant correlation between negative TWA and negative EES (p<0.001). All Ath with positive TWA also had VT induced by a EES, but without significant correlation between positive TWA and positive EES. In 2 Ath with undetermined TWA (29%) VT were induced at EES. Our data did not show significant correlation between indeterminate TWA and positive or negative EES. However, logistic regression analysis showed significant correlation between abnormal TWA test (positive or indeterminate) and inducibility of VT at EES (p<0.001). During follow-up we observed a significant difference in end-point occurrence between Ath with negative or positive TWA and between Ath with negative or positive EES. Conclusion: TWA confirm its role as a simple and non-invasive test, and it seems useful for prognostic stratification of Ath with VA. (Heart International 2007; 3: 58-67)

    • 1 October 2008
      • Vol. 9, 5S-10S

    [Non-antiarrhythmic pharmacological treatment of atrial fibrillation: focus on drugs acting on the renin-angiotensin system].

    by Ornella Durin, Claudio Pedrinazzi, Giuseppe Inama

    Atrial fibrillation is the most frequent arrhythmia in clinical practice. It is necessary to look for new therapeutic solutions because of the unsatisfactory efficacy of antiarrhythmic drugs in controlling relapses and the continuous growth of this phenomenon. The study of non-antiarrhythmic drugs that act specifically on atrial remodeling, which is the arrhythmia substrate, is a novel and very interesting field of investigation. Namely, we have been evaluating drugs that act on the renin-angiotensin system for the last few years with very promising, although not univocal, results. In this paper we discuss the rationale of their employment and review the most important data of the literature since 1999.

    • 1 October 2008
      • Vol. 9, 40S-46S

    [Non-linear analysis of electrocardiographic signals as a non-invasive predictive tool for major ventricular arrhythmias].

    by Rita Pizzi, Giuseppe Inama, Ornella Durin, Claudio Pedrinazzi

    The aim of this study was to assess the effectiveness of different methods of non-linear analysis of the ECG in the risk stratification of patients with ventricular arrhythmias. These non-invasive parameters were correlated with the results of the electrophysiological study (EPS). We evaluated 25 patients with a history of cardiac arrest, syncope, sustained or non-sustained ventricular tachycardia. The study group was compared with a control group of 25 healthy subjects. All patients underwent both EPS and non-linear analysis procedures applied to their ECG recording. A comparison between the results of non-linear analysis of the ECG and EPS was performed. Results are presented and discussed.

    • 1 October 2008
      • Vol. 9, 47S-51S

    [Usefulness of home monitoring in patients with implantable cardioverter-defibrillators].

    by Claudio Pedrinazzi, Giuseppe Inama, Ornella Durin, Claudia Vergara Munoz, Sara De Simoni, Frida Fagandini, Roberto Savazza, Luigi Ablondi

    During the last years several remote monitoring systems have been introduced in everyday clinical practice, because of the development of new computer and information technologies. Therefore, clinical and technical data of implanted devices can be transmitted by patients directly to the cardiology department through a transtelephonic web-based connection, without undergoing traditional outpatient evaluation. Home monitoring systems are effective in identifying device malfunctioning and clinical instability in patients with implantable cardioverter-defibrillators. Their efficacy does not significantly differ from that of traditional outpatient device interrogation, but with significant advantages in terms of quality of life and reduction in clinic visits for device follow-up.

    • 1 October 2008
      • Vol. 9, 52S-55S

    [Diabetes and ischemic heart disease: specific treatment].

    by Riccardo Raddino, Ivano Bonadei, Melissa Teli, Debora Robba, Giorgio Caretta, Alberto Madureri, Gregoriana Zanini, Claudio Pedrinazzi, Enrico Vizzardi, Livio Dei Cas

    Diabetes mellitus is a worldwide epidemic whose incidence and prevalence have significantly increased in recent decades. Diabetic patients have an increased mortality and morbidity related to ischemic heart disease and are more likely to develop multivessel coronary artery disease than non-diabetic patients. An acute coronary event is the leading cause of death among diabetics. These patients have an increased risk of complications after an acute coronary syndrome both during the acute phase and in the post-infarction period. Experimental evidences showed an increased prevalence of atherosclerosis as well as platelet and coagulation abnormalities in patients with diabetes, even after data adjustment for other risk factors. Both hyperglycemia and insulin resistance play a role in the pathogenic link between diabetes and atherosclerosis. Diabetic patients, therefore, could derive a greater benefit from therapies shown to be effective in treating and preventing ischemic heart disease. An aggressive correction of cardiovascular risk factors and accurate risk stratification of patients with diabetes are needed.

    • 1 October 2008
      • Vol. 9, 83S-89S

    [Current limitations and new perspectives in the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia].

    by Giuseppe Inama, Claudio Pedrinazzi, Pietro Gazzaniga, Chiara Reduzzi, Giorgio Donato, Claudia Vergara Munoz, Andrea Pacchioni, Lorenza Inama, Walter Della Frera, Ornella Durin

    Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic cardiomyopathy characterized by ventricular arrhythmias and structural abnormalities of the right ventricle. In ARVC/D there is a progressive replacement of right ventricular myocardium with fatty and fibrous tissue and ventricular arrhythmias of right ventricular origin. The precise prevalence of ARVC/D has been estimated to vary between 1 in 1000 to 1 in 5000 of the general population. ARVC accounts for approximately 3-10% of sudden deaths in young people under the age of 65 years. The purpose of this paper is to review the current knowledge of ARVC/D and its management. Particular attention will be focused on some of the recent advances in the understanding of the genetic basis of ARVC/D. Increasing evidence suggests that ARVC/D is a disease of desmosomal dysfunction. Attention will also be focused on the new and somewhat controversial concept that ARVC/D may present primarily as a left ventricular disease. In our experience ARVC/D typically presents as a right ventricular disease, unless a patient has advanced disease. Diagnosis of ARVC/D is challenging and requires a comprehensive evaluation with both non-invasive and invasive testing.


    • 1 October 2008
      • Vol. 9, 118S-122S

    [Non-pharmacological therapy of decompensated heart failure: the extracorporeal ultrafiltration].

    by Daniela Maria Tovena, Claudio Pedrinazzi, Valeria Ogliari, Giorgio De Petri, Maurizio Mileti, Giuseppe Inama

    High-dose diuretic therapy frequently leads to diuretic resistance in patients with decompensated heart failure, through several pathophysiological mechanisms. Ultrafiltration is a non-pharmacological technique that is effective in reducing fluid overload, and nowadays it can be performed out of the hemodialysis unit, because of the availability of simplified tools. The ultrafiltrate production is obtained by an extracorporeal circuit with a filter inside. The procedure requires a veno-venous access and hemodynamic stability is guaranteed by circulatory refilling at the pulmonary and systemic levels. Ultrafiltration in patients with severely decompensated heart failure can promptly reduce fluid overload, improve cardiac function, relieve symptoms, increase diuresis, restore normal plasma levels of sodium, and reduce neurohumoral activation. Several studies have demonstrated that beneficial effects of ultrafiltration are maintained also in the following period. Indeed, recently published randomized studies showed middle-term beneficial effects of ultrafiltration therapy, with a reduction of decompensated heart failure episodes and of hospitalizations due to heart failure.

  • Out-of-hospital cardiac arrest caused by transient left ventricular apical ballooning syndrome

    by Riccardo Raddino, Claudio Pedrinazzi, Gregoriana Zanini, Debora Robba, Cinzia Portera, Ivano Bonadei, Enrico Vizzardi, Livio Dei Cas